Zero Infections in High-Risk Cardiac Device Replacements Reported with Use of TYRX Antibacterial Envelope
Prospective, Multicenter Study of 532 Case Matched Patients Showed 100% Reduction in Infections
Athens, Greece (June 26, 2013): Use of TYRX, Inc.’s AIGISRx® Antibacterial Envelope reduced major infection rates by 100% in patients undergoing Cardiovascular Implantable Electronic Device (CIED) replacement procedures compared to case-matched retrospective control patients. Investigators presented new interim results from the Citadel / Centurion Clinical Study today at the Late Breaking Clinical Trials session at the European Heart Rhythm Association (EHRA), EUROPACE 2013.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.